Medtronic plc
NYSE:MDTMedical - Devices
+$0.75 today
- Market cap
- $128.84B
- Beta
- 0.60
- P/E (TTM)
- 21.1
- EPS (TTM)
- $3.74
- Dividend yield
- 3.60%
Volume 6.47M
Average 11.36M
MDT Other Financing Activities
Financing cash flows not reported separately.
Medtronic plcNYSE: MDT
Other Financing Activities · Q1 FY2027 · quarter ended Jul 2026
Other financing activities dips below year-ago levels
Q1 FY2027 other financing activities of $13M fell 81.4% year over year, behind the +630.3% change in trailing-twelve-month other financing activities. Sequentially, it fell 97.5% from the prior quarter.
Context
- Other financing activities amounted to 1.6% of revenue in FY2026, up 1.1 pp from a year earlier.
- Other financing activities increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -81.4% toward the trailing-twelve-month pace of +630.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2026
- 582M USD
- Year-over-year change
- +416.3%
- 4-year CAGR
- +37.5%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2026 | 2026-04-24 | 582M | +416.3% |
| FY2025 | 2025-04-25 | (184M) | -6033.3% |
| FY2024 | 2024-04-26 | (3M) | +97.0% |
| FY2023 | 2023-04-28 | (101M) | -162.0% |
| FY2022 | 2022-04-29 | 163M | — |
Other Financing Activities vs competitors
How MDT compares with its peers on the latest reported figures
- Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +630.3% is the 5th highest of 9, against a peer median of +756.1%.
- Other financing activities amounts to 1.4% of revenue for MDT, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $899.3M USD | +621.7% | — | 13.8% | |
| LTM Jun 2026 | $602M USD | +1924.2% | -11.7% | 2.3% | |
| LTM Jul 2026 | $525M USD | +630.3% | — | 1.4% | |
| LTM Jun 2026 | $314M USD | +890.5% | — | 3.7% | |
| LTM Jun 2026 | $158M USD | -43.2% | -26.3% | 0.8% | |
| LTM Sep 2026 | $55.62M USD | +5074.1% | — | 3.7% | |
| LTM Jun 2026 | €36.71M EUR | +3388.3% | +27.3% | 0.2% | |
| LTM Jun 2026 | $2.07M USD | +21.1% | -30.0% | 0.1% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.17M USD | -47.0% | +5.4% | 63.0% |
| Peer median (excluding MDT) | — | +756.1% | -11.7% | 3.0% | |
Competitors are the stored peer set for MDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Apr 2026 |
|---|---|---|---|---|---|
| Net Income | 5.06B | 3.78B | 3.68B | 4.69B | 4.84B |
| Depreciation & Amortization | 2.71B | 2.7B | 2.65B | 2.86B | 2.96B |
| Deferred Income Tax | (604M) | (226M) | (508M) | (316M) | 51M |
| Stock-Based Compensation | 359M | 355M | 393M | 429M | 457M |
| Change in Working Capital | (889M) | (967M) | (484M) | (1.05B) | (1.42B) |
| Accounts Receivables | (477M) | (576M) | (391M) | (433M) | (200M) |
| Inventory | (560M) | (939M) | (139M) | (292M) | (404M) |
| Accounts Payables | 213M | 696M | 391M | 209M | 46M |
| Other Working Capital | (65M) | (148M) | (345M) | (538M) | (865M) |
| Other Non-Cash Items | 711M | 396M | 1.06B | 433M | 450M |
| Operating Cash Flow | 7.35B | 6.04B | 6.79B | 7.04B | 7.33B |
| Capital Expenditures | (1.37B) | (1.46B) | (1.59B) | (1.86B) | (1.9B) |
| Acquisitions (Net) | (91M) | (1.87B) | (211M) | (98M) | (406M) |
| Purchases of Investments | (9.88B) | (7.51B) | (7.75B) | (8.23B) | (8.73B) |
| Sales of Investments | 9.69B | 7.34B | 7.44B | 8.5B | 8.11B |
| Other Investing Activities | (10M) | 4M | (261M) | (249M) | (4M) |
| Investing Cash Flow | (1.66B) | (3.49B) | (2.37B) | (1.94B) | (2.93B) |
| Debt Repayment | (1M) | (598M) | 1.07B | 2.14B | (1.17B) |
| Common Stock Issued | 429M | 308M | 284M | 508M | 516M |
| Common Stock Repurchased | (2.54B) | (645M) | (2.14B) | (3.24B) | (1.04B) |
| Dividends Paid | (3.38B) | (3.62B) | (3.67B) | (3.59B) | (3.64B) |
| Other Financing Activities | 163M | (101M) | (3M) | (184M) | 582M |
| Financing Cash Flow | (5.34B) | (4.96B) | (4.45B) | (4.36B) | (4.75B) |
| Effect of Forex Changes | (230M) | 243M | (230M) | 188M | 85M |
| Net Change in Cash | 121M | (2.17B) | (259M) | 934M | (269M) |
| Free Cash Flow | 5.98B | 4.58B | 5.2B | 5.19B | 5.43B |
Medtronic plc
NYSE:MDT
Intrinsic Alpha fair value
Locked
Current Price
$100.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.